Company Profile
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company develops drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs.
Its portfolio also includes Phyrago, an oral kinase inhibitor used to treat chronic myeloid leukemia and acute lymphoblastic leukemia, Tascenso ODT for the treatment of multiple sclerosis, and HND-033, HND-039, and HND-027 for oncology diseases Quetiapine XR to treat Schizophrenia.
Its portfolio also includes Dexlansoprazole DR capsules to treat erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease, HND-004 for treating diabetes, Varenicline tablet and HND-032 for smoking cessation, and HND-026, a GI drug. Founded in 2014, Handa Pharmaceuticals is headquartered in Tainan City, Taiwan.